Compensation And Benefits Planning

"My CPA told me: You don't have to spend your HSA — just let it grow." Last week, I reviewed a client's tax return. They contributed $8,300 to their HSA... and panicked thinking they had to spend it all. They'd been saving receipts all year, planning a December shopping spree for eligible expenses. I stopped them cold: "That's FSA thinking. Your HSA never expires." That money? Still sitting there, tax-free, compounding. Completely untaxed growth — potentially for decades. Their face when they realized their HSA could become a stealth retirement account was priceless. The HSA is the ONLY triple-tax-free account in existence: - Tax-deductible going in (immediate savings) - Grows tax-free (no capital gains taxes ever) - Withdraw tax-free for qualified medical expenses — even decades later And if you don't use it for medical expenses? At age 65, it works like a traditional IRA — withdraw for anything, just pay income tax (no penalties). Here's how to actually win with an HSA: - Max out the contribution every year ($8,300 family limit for 2024, rising to $8,550 in 2025) - Do NOT spend it. Pay medical costs out-of-pocket if you can  - Invest the HSA balance — don't leave it in cash earning nothing - Keep every medical receipt digitally. You can reimburse yourself years later, tax-free - Treat your HSA as part of your retirement portfolio — not a short-term medical fund Remember: The average couple needs $315,000 for healthcare in retirement. Your future self will thank you for this tax-free medical nest egg. If your CPA hasn't explained this strategy to you, you're leaving one of the most powerful tax advantages on the table.

Are interest rates where they should be? Our latest analysis explores the equilibrium level of interest rates, the point where rates naturally settle over time and how today’s rates compare, despite recent global shocks. Key takeaways: ▪️ The federal funds rate is currently above equilibrium, with trade policy uncertainty playing a big role. ▪️ Mortgage rates remain elevated due to bond market volatility and increased investor risk. ▪️ Corporate bond yields are lower than expected, suggesting investors are underestimating credit risk. ▪️ Long-term Treasury yields are near their equilibrium but sit in a fragile market facing political and fiscal headwinds. Even after a global pandemic, war, and economic disruption, interest rates aren’t far off track but risks remain. Read the full report to explore our framework and forecasts: https://lnkd.in/ehuN5D9N Cristian deRitis, Damien Moore, Martin Wurm #interestrates #fundsrate #EquilibriumRate

4 year long grants are no longer the market standard–be very careful when looking at equity compensation benchmarks The simple way to do equity benchmarking is –1) Look at new hire equity target benchmarks –2) Use those benchmarks to directly inform your company’s new hire targets for total grant size But if you’re looking at benchmarks that mix 1, 2, 3, and 4 year grants into the same sample set, you’re at risk of mixing apples and bananas in a way that can substantially impact your equity comp accuracy and SBC over time. To take a step back, let’s take a look at how the market standards for equity vesting durations have evolved over the past five years for private and public companies across both new hire and ongoing (refresh) grants. _______________ 𝗧𝗵𝗲 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗼𝗿 𝗡𝗲𝘄 𝗛𝗶𝗿𝗲 𝗚𝗿𝗮𝗻𝘁𝘀: ↗️ 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 => the average new hire grant has increased from 3.2 to 4.0 years from 2020 to 2025 ↘️ 𝗣𝘂𝗯𝗹𝗶𝗰 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 => the average new hire grant has decreased from 3.4 to 3.0 years from 2020 to 2025 _______________ 𝗧𝗵𝗲 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗼𝗿 𝗢𝗻𝗴𝗼𝗶𝗻𝗴 (𝗥𝗲𝗳𝗿𝗲𝘀𝗵) 𝗚𝗿𝗮𝗻𝘁𝘀: ➡️ 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 => the average ongoing grant has stayed most flat at around ~3.5 years ↘️ 𝗣𝘂𝗯𝗹𝗶𝗰 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 => the average ongoing grant has decreased from 3.6 to 2.9 years from 2020 to 2025 _______________ 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: 1️⃣ 𝟰 𝘆𝗲𝗮𝗿 𝗴𝗿𝗮𝗻𝘁𝘀 𝗮𝗿𝗲 𝗡𝗢𝗧 𝘁𝗵𝗲 𝘂𝗯𝗶𝗾𝘂𝗶𝘁𝗼𝘂𝘀 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱. In particular, the average public company grant is now ~3.0 years in length for both new hire and ongoing grants. And even private company ongoing grants are averaging ~3.5 years in length these days. 2️⃣ 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗻𝗲𝘄 𝗵𝗶𝗿𝗲 𝗴𝗿𝗮𝗻𝘁𝘀 𝗵𝗮𝘃𝗲 𝗺𝗼𝘀𝘁𝗹𝘆 𝗿𝗲𝘁𝘂𝗿𝗻𝗲𝗱 𝘁𝗼 𝟰.𝟬 𝘆𝗲𝗮𝗿𝘀 after a period of exploration with shorter grants during Covid and the ZIRP era. _______________ 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗲𝗾𝘂𝗶𝘁𝘆 𝗰𝗼𝗺𝗽 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸𝗶𝗻𝗴: As mentioned above, the anti-pattern that I frequently see is when companies perform their equity comp market analyses on total equity grant sizes rather than annualized equity grants. This is the typical way of working with traditional survey providers, for instance. But it is a fairly substantial misstep given the now commonplace experimentation of varying vesting durations across the market today. When looking at equity benchmarks, 𝗜 𝘀𝘁𝗿𝗼𝗻𝗴𝗹𝘆 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗮𝘁 𝗮𝗻𝗻𝘂𝗮𝗹𝗶𝘇𝗲𝗱 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸𝘀 and then backing into your company’s equity program (2 year, 3 year, 4 year, etc grants).

Interest rates are not just numbers… they are a reflection of an economy’s stress, stability, and strategy. Look at the extremes. Turkey at 37% and Argentina at 29% — these aren’t “high returns,” they are signals of deep inflation, currency pressure, and economic instability. When rates go this high, it means central banks are fighting to control the system, not grow it. Now compare that with developed economies. The U.S. and UK at ~3.75%, Euro Area at ~2.15%, and Singapore below 1%. These numbers reflect controlled inflation, stable currencies, and mature financial systems. Lower rates here don’t mean weakness — they mean confidence and balance. Then comes the interesting middle. India at 5.25%, Brazil/South Africa/Mexico around ~6.75%. These are growth economies balancing inflation and expansion. Rates are higher than developed markets because growth is faster — but not so high that they choke demand. This is where the real insight lies: 👉 High rates = stress management 👉 Low rates = stability 👉 Moderate rates = growth balancing And this directly impacts markets. When rates are high → borrowing is expensive → consumption slows → equity markets struggle When rates fall → liquidity increases → risk assets rally Which means, interest rates are not just macro data… They are the biggest driver of market cycles. Smart investors don’t just track stocks. They track liquidity. Because in the end, markets don’t move on stories… They move on money flow. Image Source: Trading Economics Follow Chitranjan Singh for more such insights!! #InterestRates #MacroEconomics #Investing #StockMarket #GlobalEconomy #Liquidity

The trucking rate mirage has reappeared… Most freight chart aficionados like to study rates excluding fuel. Why? Because these higher-level analyses and trends aim to study how market forces move rates up and down. Fuel moves to the beat of its own drum. It doesn't go up or down based on the demand for shipping or the number of trucks on the road. On the contract side, it's included in the agreement as a defined fuel surcharge. Things get trickier in the spot market since almost all loads are negotiated all-in with no separate fuel surcharge. Most analytics providers have a method for normalizing out fuel to arrive at a linehaul approximation for spot rates. The mirage I referenced that's happening right now is that all-in spot rates appear to be increasing as a result of fuel prices spiking. But when we adjust for fuel, the linehaul allocation is contracting rapidly. What this means in reality is that carriers are unable to negotiate on a load-by-load basis for the full increase in fuel that they're realizing at the pump. Rates are ticking up, but not nearly at the pace with which fuel prices are increasing. This phenomenon generally resolves itself over time as things normalize. In the interim, it's critical that shippers, brokers, and carriers monitor all components of their freight spend.

I used to market benchmark roles one at a time. Every new hire. Every promotion. Every pay review. Compensation bands changed everything.   At first, it was just about saving time.   I'd try to benchmark a role as the need arose, but as the company grew, the problems quickly grew with it.   Manually benchmarking roles were: - Always reactive to a need (hiring, counter-offers etc.) - Manual and time consuming - Prone to inconsistencies Worse yet - Each individual benchmark required approval, slowing me (and the business) further.   I was effectively building our comp logic every time a decision needed to be made.   It was slow, chaotic, and risky, and it wasn't a great credibility builder for me or the People function.   Then my eyes were opened to how things could be by building compensation bands.   That by crafting a set of salary bands informed by the market data but built to our comp philosophy, we could proactively solve for our needs.   I built something that was: - Based on benchmark data, but internalised to fit our strategy - Allowed hiring managers, talent acquisition and anyone that needed it to have the data they required (in a click) - Enable fair, consistent decisions at scale   This simple shift also made pay equity and level progression visible and manageable.   And yeah, while it takes some effort upfront, the downstream gains are massive.   When you have bands: ✅ You don’t have to explain your logic every time ✅ You don’t bottleneck at the Head of People or Finance ✅ You stop redoing work that could’ve been decided once and reused 100 times ✅ You make decisions faster — and fairer   Comp bands were a huge efficiency enabler.   And every startup that’s scaling beyond 50 people needs this. Because the cost of doing it ad hoc is compounding every quarter.   What's your biggest challenge when building comp bands?

"No budget for promotions right now" but plenty of budget to benefit from your expanded expertise? Time for strategic action. If you're a biotech/pharma professional stuck doing senior-level work for mid-level pay, here's your playbook for getting proper recognition: 📊 Lead with industry-specific impact data: - "Managed 3 Phase II studies with 847 patients, 95% retention, completed 2 months early = $1.2M saved" - "Led FDA interactions for 4 INDs, 0 clinical holds, accelerated timelines by 6 weeks per program" - "Directed CMC strategy for biologics program, enabling $50M Series B based on manufacturing readiness" 💰 Benchmark against industry standards: Research compensation data from Biospace, Glassdoor, industry salary surveys. Present evidence: "Based on benchmarking, professionals with my scope typically hold [target title] with compensation ranges of $X-Y." 🎯 Frame conversations around business impact: Sample script: "I've been managing responsibilities across [specific areas] that typically align with [target role]. In the last [period], I delivered [quantified outcomes]. I'd like to discuss aligning my title and compensation with my current scope and value delivery." ⚡ Know your leverage: In biotech/pharma, specialized knowledge = currency. Emphasize how replacing your institutional knowledge would impact project timelines and development costs. Companies invest millions in programs, but proper compensation is minimal compared to knowledge-loss risk. The reality: If they consistently deflect with "budget constraints" as a permanent excuse, that's valuable data about their priorities and your growth potential there. Your specialized expertise deserves specialized compensation. What's worked for you in biotech/pharma compensation negotiations? Share your wins or DM me for positioning strategies. #BiotechCareers #PharmaCareers #Negotiation #SalaryNegotiation #ClinicalDevelopment

𝗧𝗵𝗲 𝗧𝗿𝗶𝗽𝗹𝗲-𝗧𝗮𝘅 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 𝗥𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗩𝗲𝗵𝗶𝗰𝗹𝗲 𝗧𝗵𝗮𝘁'𝘀 𝗡𝗼𝘁 𝗮 𝟰𝟬𝟭(𝗸) 🏥💰 For high-income earners, maximizing traditional retirement accounts is only Step 1. To unlock truly advanced tax savings, you need to look at the 𝗛𝗲𝗮𝗹𝘁𝗵 𝗦𝗮𝘃𝗶𝗻𝗴𝘀 𝗔𝗰𝗰𝗼𝘂𝗻𝘁 (𝗛𝗦𝗔). It's arguably the most powerful savings vehicle in the tax code because it offers a triple tax advantage that no other account provides. The HSA is 𝗼𝗳𝘁𝗲𝗻 𝗺𝗶𝘀𝗹𝗮𝗯𝗲𝗹𝗲𝗱 𝗮𝘀 𝗷𝘂𝘀𝘁 𝗮 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗮𝗰𝗰𝗼𝘂𝗻𝘁. It's actually a 𝗿𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲 when used correctly (as an investment account). 𝗧𝗮𝘅-𝗗𝗲𝗱𝘂𝗰𝘁𝗶𝗯𝗹𝗲 𝗖𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻𝘀: Money goes in pre-tax (or is fully deductible as an "above-the-line" deduction), lowering your current year's Adjusted Gross Income (AGI). 𝗧𝗮𝘅-𝗙𝗿𝗲𝗲 𝗚𝗿𝗼𝘄𝘁𝗵: The money, and all investment earnings, grow tax-free. 𝗧𝗮𝘅-𝗙𝗿𝗲𝗲 𝗪𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹𝘀 (𝗳𝗼𝗿 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗲𝘅𝗽𝗲𝗻𝘀𝗲𝘀): When you take money out - at any age - for qualified medical expenses, it's completely tax-free. 🔑 𝗧𝗵𝗲 𝗥𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗦𝘂𝗽𝗲𝗿𝗽𝗼𝘄𝗲𝗿 (𝗔𝗴𝗲 𝟲𝟱+): 𝗡𝗼 𝗣𝗲𝗻𝗮𝗹𝘁𝗶𝗲𝘀: After age 65, you can withdraw the money for any purpose without the 20% penalty. 𝗟𝗶𝗸𝗲 𝗮 𝟰𝟬𝟭(𝗸): Withdrawals for non-medical expenses are simply taxed as ordinary income, just like a traditional 401(k) or IRA. 𝗡𝗼 𝗥𝗠𝗗𝘀: Unlike a 401(k) or IRA, there are no Required Minimum Distributions (RMDs), giving you ultimate control over the money's growth. 𝟮𝟬𝟮𝟱 𝗛𝗦𝗔 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴: To open and contribute to an HSA, you must be enrolled in a High-Deductible Health Plan (HDHP) - check the snip attached. 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: 𝗧𝗵𝗲 𝗥𝗲𝗰𝗲𝗶𝗽𝘁 𝗦𝗵𝗼𝗲𝗯𝗼𝘅 🧾: Pay for your current medical expenses out-of-pocket (from non-HSA funds) and keep every receipt. Because HSA funds roll over and are portable, you can let your HSA money stay invested and grow for decades. You can then reimburse yourself tax-free at any point in the future - even in retirement - for those old, qualified expenses. This allows you to turn your HSA into a massive, tax-free emergency retirement fund. 𝗔𝗿𝗲 𝘆𝗼𝘂 𝘂𝘀𝗶𝗻𝗴 𝗮𝗻 𝗛𝗗𝗛𝗣 𝘁𝗼 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗲 𝘆𝗼𝘂𝗿 𝗛𝗦𝗔, 𝗼𝗿 𝗮𝗿𝗲 𝘆𝗼𝘂 𝗺𝗶𝘀𝘀𝗶𝗻𝗴 𝗼𝘂𝘁 𝗼𝗻 𝘁𝗵𝗶𝘀 "𝘀𝗲𝗰𝗿𝗲𝘁" 𝗿𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝘃𝗲𝗵𝗶𝗰𝗹𝗲? #linkedinforcreators

After 20+ years of recruiting in the #brake industry — and thousands of conversations with engineers, formulators, sales leaders, and executives — I've noticed something that keeps coming up: Most people in this industry have no idea what the person sitting across the table from them actually makes. That's not a knock. It's just reality. The brake world is niche enough that general salary surveys don't capture it, and most people aren't exactly comparing notes at the SAE Brake Colloquium. So we built something to fix that. The 2026 Brake Industry Compensation & Talent Report covers real-world salary ranges for the roles I recruit for every day — friction material formulators, NVH engineers, quality managers, brake sales directors, plant managers, and more. It's free. No strings attached. Just good data for an industry that deserves better benchmarks. Download it here: https://lnkd.in/giHMH-kr If you're a hiring manager building an offer or a candidate weighing your options, this was built for you.

What’s one of the most unsuspecting, powerful items in a retirement planning tool kit? I suggest it’s the Health Savings Account, or HSA. These accounts have long been viewed as a place to save money for routine medical expenses. That’s true – and at Schwab, we suggest keeping two to three years’ worth of routine medical expenses in cash, cash investments, or similar low-volatility investments within your HSA. After that, any excess funds could be invested for potential growth – making these accounts powerful retirement planning tools. Making the retirement case stronger, HSAs aren’t subject to required minimum distributions. I recently talked to Adam Shell at Investor’s Business Daily about how HSAs can be particularly advantageous for younger investors. As Adam wrote in his recent article, … “younger investors have a longer runway for their dollars to grow. They can reap the biggest benefits.” Adding to HSA’s appeal, after age 65, you can use your HSA to pay for things other than health care (but you will owe ordinary income tax on the funds). They’re not perfect, of course. To contribute to an HSA you have to first have an eligible high-deductible health care plan (usually from your employer). Contribution limits apply, and most HSAs require you to have a certain amount in cash saved in the account before you can start to invest. Learn more about the power of HSAs in this Schwab article: Potential Long-Term Benefits of Investing Your HSA: Potential Long-Term Benefits of Investing Your HSA https://lnkd.in/g9CzjBTE #HSA #millennialinvestors